Citations

Clear

3314 citation(s) found for "Do, Alexander".

Quality Improvement Goals for Acute Kidney Injury
Kashani, Kianoush , Rosner, Mitchell H. , Lewington, Andrew , O’Donoghue, Dónal , Wilson, F. Perry , Nadim, Mitra K. , Silver, Samuel A. , Zarbock, Alexander , Ostermann, Marlies , Mehta, Ravindra L. , Kane‐Gill, Sandra L. , Pickkers, Peter , Bihorac, Azra , Siew, Edward D. , Frazee, Erin N. , Macedo, Etienne , Kellum, John A. , Tolwani, Ashita , Ronco, Claudio , Juncos, Luis A. , Rewa, Oleksa , Bagshaw, Sean M. , Mottes, Theresa , Liu, Kathleen D. , Heung, Michael , Wu, Vin‐Cent , Rewa, Oleksa G. , Wilson, F Perry , Mehta, Ravindra L , Ding, Xiaoqiang , Frazee, Erin N , Macedo, Etienne , Ronco, Claudio , Wu, Vin-Cent , Kane-Gill, Sandra L , Kashani, Kianoush B , Kellum, John A , Silver, Samuel A , Haase, Michael , Palevsky, Paul M. , Koyner, Jay L. , Forni, Lui G. , Bihorac, Azra , Bagshaw, Sean M , Juncos, Luis A , Ostermann, Marlies , Rewa, Oleksa G , Siew, Edward D

Mayo Clinic

Clinical Journal of the American Society of Nephrology | May 17, 2019 | Volume: 14 | Issue: 6 | Pages: 941-953

10.2215/cjn.01250119 | PMID 31101671 Get It

AKI is a global concern with a high incidence among patients across acute care settings. AKI is associated with significant clinical consequences and increased health care costs. Preventive measures, as well as rapid identification of AKI, have been shown to improve outcomes in small studies. Providing high-quality care for patients with AKI or those at risk of AKI occurs across a continuum that starts at the community level and continues in the emergency department, hospital setting, and after discharge from inpatient care. Improving the quality of care provided to these patients, plausibly mitigating the cost of care and improving short- and long-term outcomes, are goals that have not been universally achieved. Therefore, understanding how the management of AKI may be amenable to quality improvement programs is needed. Recognizing this gap in knowledge, the 22nd Acute Disease Quality Initiative meeting was convened to discuss the evidence, provide recommendations, and highlight future directions for AKI-related quality measures and care processes. Using a modified Delphi process, an international group of experts including physicians, a nurse practitioner, and pharmacists provided a framework for current and future quality improvement projects in the area of AKI. Where possible, best practices in the prevention, identification, and care of the patient with AKI were identified and highlighted. This article provides a summary of the key messages and recommendations of the group, with an aim to equip and encourage health care providers to establish quality care delivery for patients with AKI and to measure key quality indicators.
Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis
Gelbard, Alexander , Sibley, Cailin H. , Sirajuddin, Arlene , Ferrada, Marcela A. , Chen, Marcus Y. , Cuthbertson, David , Carette, Simon , Koening, Curry L. , Langford, Carol A. , McAlear, Carol A. , Moreland, Larry W. , Sreih, Antoine G. , Ytterberg, Steven R. , Grayson, Peter C. , Moreland, Larry W , Gelbard, Alexander , Khalidi, Nader , Monach, Paul A. , Pagnoux, Christian , Seo, Philip , Specks, Ulrich , Merkel, Peter A. , Ferrada, Marcela A

Mayo Clinic

Rheumatology | May 10, 2019 | Volume: 58 | Issue: 12 | Pages: 2203-2211

10.1093/rheumatology/kez217 | PMID 31199488 Get It

Abstract Objectives To describe tracheobronchial disease in patients with granulomatosis with polyangiitis (GPA) and evaluate the utility of dynamic expiratory CT to detect large-airway disease. Methods Demographic and clinical features associated with the presence of subglottic stenosis (SGS) or endobronchial involvement were assessed in a multicentre, observational cohort of patients with GPA. A subset of patients with GPA from a single-centre cohort underwent dynamic chest CT to evaluate the airways. Results Among 962 patients with GPA, SGS and endobronchial disease were identified in 95 (10%) and 59 (6%) patients, respectively. Patients with SGS were more likely to be female (72% vs 53%, P < 0.01), younger at time of diagnosis (36 vs 49 years, P < 0.01), and have saddle-nose deformities (28% vs 10%, P < 0.01), but were less likely to have renal involvement (39% vs 62%, P < 0.01). Patients with endobronchial disease were more likely to be PR3-ANCA positive (85% vs 66%, P < 0.01), with more ENT involvement (97% vs 77%, P < 0.01) and less renal involvement (42% vs 62%, P < 0.01). Disease activity in patients with large-airway disease was commonly isolated to the subglottis/upper airway (57%) or bronchi (32%). Seven of 23 patients screened by dynamic chest CT had large-airway pathology, including four patients with chronic, unexplained cough, discovered to have tracheobronchomalacia. Conclusion SGS and endobronchial disease occur in 10% and 6% of patients with GPA, respectively, and may occur without disease activity in other organs. Dynamic expiratory chest CT is a potential non-invasive screening test for large-airway involvement in GPA.
SUN-LB044 Effects of Glucagon-Like Peptide-1 (GLP-1) on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men
Crustna, Yoshibye, Machenahalli, Pratibha, Papadopoulou, Deborah , Panayi, Christos, Starikova, Jessica , Yang, Lisa, Ratnasabapathy, Risheka , Sykes, Mark, Plumptre, Bella, Tharakan, George, Veldhuis, Johannes D. , Comninos, Alexander , Izzi‐Engbeaya, Chioma , Jones, Sophie , Modi, Manish , Eng, Pei Chia , Phylactou, Maria , Mills, Edouard , Abbara, Ali , MINNION, JAMES S. , Tan, Tricia , Dhillo, Waljit S.

Mayo Clinic

Journal of the Endocrine Society | May 10, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: No page available

10.1210/js.2019-sun-lb044 Get It

OR11-4 Determining the Relationship between Hot Flushes and LH Pulses in Menopausal Women Using Mathematical Modelling
Comninos, Alexander , Roberts, Rachel , Yang, Lisa, Veldhuis, Johannes D. , Tsaneva‐Atanasova, Krasimira , Dhillo, Waljit S. , Prague, Julia , Voliotis, Margaritis , Clarke, Sophie , Abbara, Ali , Jayasena, Channa , McArdle, Craig A.

Mayo Clinic

Journal of the Endocrine Society | May 10, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: No page available

10.1210/js.2019-or11-4 Get It

Abstract B42: Overexpression of ENRAGE is an obesity-related alteration in clear cell renal cell carcinoma
Eckel‐Passow, Jeanette E. , Serie, Daniel, Cheville, John C. , Parker, Alexander S. , Bot, Brian M. , Joseph, Richard W. , Hart, Steven N.

Mayo Clinic

Cancer Prevention Research | May 9, 2019 | Volume: 6 | Issue: 11_Supplement | Pages: B42-B42

10.1158/1940-6215.prev-13-b42 Get It

Abstract Background: The incidence of renal cell carcinoma (RCC) in the United States (U.S.) continues to rise and this trend cannot be fully attributed to incidental detection via increased use of abdominal imaging. Related to this, obesity rates have been rising steadily in the U.S. for several decades and obesity is one of the most widely accepted risk factors for the development of RCC. Interestingly, to date there are limited data regarding the molecular mechanisms that link obesity with an increased risk of RCC. Moreover, the few studies that have investigated the molecular underpinnings that link obesity and RCC have all used a candidate gene approach focusing exclusively on evaluation of germline genetic alterations (i.e., host genetics) and not somatic alterations in the tumor itself. Motivated by this, we used a multi-stage design to identify and validate genes that are associated with obesity-related clear cell RCC (ccRCC). Methods: We conducted a gene-expression microarray study of ccRCC and compared gene expression between 19 obese and 46 non-obese patients in both ccRCC tumors and patient-matched normal kidney tissues. Analyses were first stratified by smoking status, the other widely acceptable risk factor for RCC, and subsequently performed on the pooled cohort. To identify genes that are specific to obesity-related ccRCC, we identified Affymetrix probesets that had a tissue type-by-obesity status interaction p-value <0.01 amongst non-smokers (stage 1), an interaction p-value <0.05 in patients with a history of smoking (stage 2) and an interaction p-value<0.01 in the pooled analysis (stage 3). Lastly, targeted validation was performed via RT-PCR on an independent cohort of 19 obese and 54 non-obese patients in both ccRCC tumors and patient-matched normal kidney tissues (stage 4). In addition to evaluating differential expression, an enrichment analysis was performed using DAVID and the results were compared to the Genetic Association Database. Results: From our microarray analyses, we identified two genes and one non-coding RNA as having candidate associations with obesity-related ccRCC: EFCAB6, ENRAGE and NCRNA00263, respectively. Using RT-PCR, we validated that while expression of ENRAGE is similar in normal kidney tissue across obese and non-obese subjects, ENRAGE is significantly over expressed in ccRCC tissues from obese patients compared to non-obese subjects. Others have shown that ENRAGE is a useful biomarker of inflammation and has a positive association with visceral fat adiposity, which provides further credence to our observations. As an alternative analysis approach, using the Genetic Association Database to identify medically-relevant somatic features, we also observed a putative relationship between GAL, IL6R, NMB and SORBS1 with obesity. Although the results of this alternative analysis approach are exploratory and thus need to be validated, there are some interesting relationships to note. Particularly, several variants in IL6R have been previously linked to obesity, diabetes and fat mass. Also, GAL is thought to play a role in drug resistance to chemotherapy in cell lines, warranting continued investigation to see if obese individuals with high or low expression show differential drug response. Conclusions: We provide evidence that overexpression of ENRAGE in ccRCC tumor tissue is an obesity-associated alteration. Up regulation of ENRAGE could lead to local, autocrine stimulation of the RAGE receptor and thus support cancer progression. Additionally, we show evidence of a putative relationship between GAL, IL6R, NMB and SORBS1 with obesity; however, these results need to be validated. Citation Format: Jeanette E. Eckel-Passow, Daniel J. Serie, Brian M. Bot, Richard W. Joseph, Steven N. Hart, John C. Cheville, Alexander S. Parker. Overexpression of ENRAGE is an obesity-related alteration in clear cell renal cell carcinoma. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr B42.
Abstract A62: Alcohol consumption, genetic variation in alcohol dehydrogenase genes, and risk of clear cell renal cell carcinoma
Parker, Alexander S. , Diehl, Nancy N. , Rivera, Shauna, Custer, Kaitlynn, Leibovich, Bradley C. , Arnold, Michelle L. , Cannon, Ashley

Mayo Clinic

Cancer Prevention Research | May 9, 2019 | Volume: 6 | Issue: 11_Supplement | Pages: A62-A62

10.1158/1940-6215.prev-13-a62 Get It

Abstract Introduction: An inverse association between alcohol consumption and risk of renal cell carcinoma (RCC) is well reported in the literature. Despite this, no investigators have explored the potential for effect modification of this association by genetic variations in enzymes that metabolize alcohol. Motivated by this, we conducted a pilot investigation of the role of genetic variation in the alcohol dehydrogenase genes (ADH) as an effect modifier of the association of alcohol and RCC risk. Methods: We analyzed data on 121 RCC cases and 121 controls. Cases were prospectively collected as part of our Renal Registry in the Department of Urology. Controls were recruited through the Family Medicine and frequency matched to cases on age, gender and state of residence. We collected detailed risk factor data (self-report questionnaire) as well as a DNA sample on cases and controls. We utilized Sequenome analysis to determine presence of published SNPs in the ADH gene cluster (ADH1-7). We employed logistic regression with interaction terms as well as stratified analyses to evaluate effect modification by genetic variants in the ADH gene cluster on the association of alcohol consumption and RCC risk. Results: Compared to non-drinkers, those that consumed alcohol above the median experienced a lowering in RCC risk (OR=0.80; 95% CI 0.5 to 1.43). We observed evidence of interactions with 6 SNPs in the ADH gene (p-values from 0.05-0.2). As an example, in stratified analysis, the inverse association strengthened in those without the minor allele present at rs1154454 in ADH7 (OR=0.56; 95% CI 0.3 to 1.0; p=0.08) while evidence of an increased in RCC risk was noted among those with the minor allele (OR=2.14; 95CI 0.8 – 5.7; p=0.1). Adjustment for age and gender did not alter our results. Conclusion: Our pilot data suggest that specific variants in the ADH gene cluster may modify the reported protective effect of alcohol consumption on RCC risk. Given the possible implications for improving our understanding of the biology of this association and informing prevention, future investigations that analyze a larger sample size and examine additional variants are warranted. Citation Format: Alexander Scott Parker, Nancy Diehl, Michelle L. Arnold, Shauna Rivera, Ashley Cannon, Kaitlynn Custer, Bradley Leibovich. Alcohol consumption, genetic variation in alcohol dehydrogenase genes, and risk of clear cell renal cell carcinoma. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr A62.
Abstract A52: ZIP11 and susceptibility to renal and bladder cancer
Wu, Lang , Parker, Alexander S. , Petersen, Gloria M. , Rabe, Kari G.

Mayo Clinic

Cancer Prevention Research | May 9, 2019 | Volume: 6 | Issue: 11_Supplement | Pages: A52-A52

10.1158/1940-6215.prev-13-a52 Get It

Abstract Introduction: Laboratory studies have demonstrated that zinc and zinc transporters play important roles in the development of urological cancers, including prostate, bladder, and renal cell cancer. To date however, there have been no efforts to evaluate whether germline variation in zinc transporter genes alter the risk of developing these cancers. Motivated by this, we evaluated associations of known variants in zinc transporter genes with risk of prostate, bladder, and renal cell cancer using three NCI Genome Wide Association Study (GWAS) data sets downloaded from dbGaP. Methods: Data consisted of GWAS data from the PLCO Screening Trial (prostate; 1172 cases, 1157 controls); Bladder Cancer study (3527 cases, 5119 controls); and Renal Cancer study (1453 cases, 3531 controls). All genotyped variants in 10 ZNT family genes (ZNT1-ZNT10) and 14 ZIP family genes (ZIP1-ZIP14) in each data set were analyzed by logistic regression models to evaluate the association of each variant with risk of developing prostate, bladder, and renal cancer, respectively. We evaluated these associations in a univariable setting, after adjusting for available covariates, such as age and gender. Correction for multiple comparisons used Max T permutation tests. Results: One variant in ZIP11, rs8081059, was associated with increased risk of renal cancer (OR=1.28, 95% CI= 1.13-1.45; corrected p= 0.049). Another ZIP11 variant, rs11871756, was associated with an increased risk of bladder cancer risk (OR=1.43, 95% CI 1.24-1.63; corrected p=0.0002). We also found three variants in ZIP11 associated with a decreased risk of bladder cancer: rs11077654 (OR=0.76, 95% CI 0.68-0.85; corrected p=0.001), rs9913017 (OR=0.76, 95% CI= 0.68-0.85; corrected p=0.002), and rs4969054 (OR=0.78, 95% CI 0.69-0.88; corrected p=0.02). Interestingly, these three protective variants are within the same LD block. There were no associations between zinc transporter variants and prostate cancer risk. Conclusion: We report for the first time that specific genetic variants of a zinc transporter gene, ZIP11, are associated with risk of renal and bladder cancer. If validated in larger, more focused studies, further investigations are warranted to explore the functional significance of ZIP11 in these two cancers. Citation Format: Lang Wu, Kari G. Rabe, Alexander S. Parker, Gloria M. Petersen. ZIP11 and susceptibility to renal and bladder cancer. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr A52.
The role of echocardiography for quantitative assessment of right ventricular size and function in adults with repaired tetralogy of Fallot
Egbe, Alexander C. , Pislaru, Sorin V. , Kothapalli, Srikanth, Jadav, Raja, Angirekula, Mounika, Pellikka, Patricia A. , Masood, Muhammad, Sabbah, Michael S. , Pellikka, Patricia A , Masood, Muhammad

Mayo Clinic

Congenital Heart Disease | May 9, 2019 | Volume: 14 | Issue: 5 | Pages: 700-705

10.1111/chd.12783 | PMID 31070871 Get It

Sex Matters in Health and Disease: a review of biological sex differences with an emphasis on glioma
Whitmire, Paula , Doyle, Tatum E, Ippolito, Joseph E. , Mrugała, Maciej M. , Hu, Leland , Canoll, Peter , Fitzpatrick, Susan M., Swanson, Kristin R. , Swanson, Kristin R , Ippolito, Joseph E , Massey, Susan Christine , Anderson, Alexander R.A. , Wilson, Melissa A. , McCarthy, Margaret M. , Rubin, Joshua B

Mayo Clinic

No container title available | May 9, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7287/peerj.preprints.27716v1 Get It

Humans are sexually dimorphic, with sex being the most persistent difference among humans over the course of our evolutionary history. Beyond the visible sex differences that can be considered true dimorphisms, there are also sex differences at the molecular and cellular scales. The role of these biological sex differences for human health, while being increasingly recognized, have long been underappreciated and underexplored. Frequently, these differences are only recognized in sex–specific diseases, such as genitourinary diseases and cancers. However, given the evidence for sex differences in the most basic aspects of human biology, including metabolism, cellular composition, and immune activity, these differences could have consequences for the etiology and pathophysiology of a majority of diseases. It is thus essential to consider the extent to which these differences may influence the various mechanisms underlying disease processes, response to treatment, and the maintenance of health in order to better improve patient outcomes. Here we review the evidence for a broad array of biological sex differences in humans and discuss how they may relate to observed sex differences in various diseases, with an emphasis on cancer, specifically glioblastoma. We further propose that mathematical approaches can be useful for exploring the extent to which sex differences affect disease outcomes and accounting for those in the development of therapeutic strategies.